Recent Updates
Recently added Catalysts
NVCT Positive Sentiment

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Tuesday, March 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nuvectis Pharma has announced that it will present its drug candidate NXP900 at the 2026 American Association for Cancer Research Meeting in San Diego. NXP900 is an oral small molecule inhibitor targeting SRC Family of Kinases, which has completed a Phase 1a study and initiated Phase 1b. This presentation highlights the company's commitment to developing innovative oncology treatments.
Price reaction · baseline $7.49 (2026-03-30 close) · hit after-hours · clean, no other NVCT news in the window
day 0 close · peak
+3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nuvectis Pharma is actively presenting at a major oncology conference.
  • NXP900 shows promise as a novel treatment with a unique mechanism of action.
  • The company has successfully completed early-phase studies for NXP900.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
6%
average across 4 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NXP900
Phase 1 · EGFR Mutation Positive Non-small Cell Lung Cancer

Full Press Release Details

Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR), taking place from April 17th to April 22nd in San Diego, CA.
Abstract Title Poster Presentation Details
NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models Session TitleCombination Targeted TherapySession Date / TimeApril 21st, 2:00 PM – 5:00 PM PT
Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy Session TitleNovel Strategies to Reverse Drug ResistanceSession Date / TimeApril 22nd, 9:00 AM – 12:00 PM PT
Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity in non-small cell lung cancer (NSCLC) via SRC family kinase Inhibition with NXP900 Session TitleTyrosine Kinase, Phosphatase, and Other InhibitorsSession Date / TimeApril 21st, 2:00 PM – 5:00 PM PT

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program has been initiated.
For more information on Nuvectis, please visit our website athttps://nuvectis.com/.

Frequently Asked Questions

What is NXP900?

NXP900 is an oral small molecule inhibitor targeting SRC Family of Kinases.

When is the 2026 AACR Meeting?

The 2026 AACR Meeting will take place from April 17th to April 22nd.

What studies has NXP900 completed?

NXP900 has completed a Phase 1a dose escalation study and a drug-drug interaction study.

Where will the AACR Meeting be held?

The 2026 AACR Meeting will be held in San Diego, CA.

ShareAdd on Google
Tags: NVCT Viatris Investor Conferences Healthcare Nuvectis Pharma NXP900 AACR 2026 oncology SRC Family of Kinases
Last updated: Mar 31, 2026

Biotech snapshot

Cash runway
$22M liquidity · $2M/mo burn
~14 mo
Low dilution risk
Lead asset
NXP900Phase 1
EGFR Mutation Positive Non-small Cell Lung Cancer →

Catalyst track record

+57%
best trade around NVCT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NVCT.

See every catalyst's timing & PoA →